Novartis is up 7.5%, or $6.24 to $89.83.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NVS:
- Novartis’ NATALEE readout a ‘best case scenario,’ says BofA
- Morgan Stanley expects Novartis to outperform after Kisqali ‘positive surprise’
- Novartis says Kisqali Phase 3 NATALEE trial met primary endpoint at interim
- Novartis Up after Positive Topline Data
- 23andMe pilots program to raise awareness about Lipoprotein(a)